share_log

PolyPid Updates On SHIELD II Trial Amidst KOL Insights On Surgical Site Infection Prevention

ポリピッドは、手術部位感染予防のKOL洞察を伴うSHIELD II試験の更新を発表しました。

Benzinga ·  06/18 07:18
  • After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels
  • Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs
  • Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II
  • Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする